These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33880083)

  • 21. Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients.
    Freeman L; Kee A; Tian M; Mehta R
    Clinicoecon Outcomes Res; 2021; 13():65-75. PubMed ID: 33519217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.
    Burks J; Marshall TS; Ye X
    Clinicoecon Outcomes Res; 2017; 9():251-260. PubMed ID: 28496344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis.
    Freedman MS; Duquette P; Grand'Maison F; Lee L; Vorobeychik G; Lara N; Khurana V; Nakhaipour HR; Schecter R; Haddad P
    Curr Med Res Opin; 2019 May; 35(5):767-776. PubMed ID: 30614288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
    Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
    J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
    Braune S; Lang M; Bergmann A;
    J Neurol; 2016 Feb; 263(2):327-333. PubMed ID: 26645389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
    Vollmer B; Ontaneda D; Harris H; Nair K; Bermel RA; Corboy JR; Fox RJ; Vollmer T; Cohen JA; Alvarez E; Hersh CM
    J Neurol Sci; 2019 Dec; 407():116498. PubMed ID: 31644992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
    Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
    Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment Patterns, Healthcare Resource Utilization, and Costs Among Medicare Patients with Multiple Sclerosis in Relation to Disease-Modifying Therapy and Corticosteroid Treatment.
    Sanchirico M; Caldwell-Tarr A; Mudumby P; Hashemi L; Dufour R
    Neurol Ther; 2019 Jun; 8(1):121-133. PubMed ID: 30565050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis.
    Earla JR; Hutton GJ; Thornton JD; Chen H; Johnson ML; Aparasu RR
    Explor Res Clin Soc Pharm; 2021 Jun; 2():100021. PubMed ID: 35481133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.
    Teter B; Agashivala N; Kavak K; Chouhfeh L; Hashmonay R; Weinstock-Guttman B
    Mult Scler; 2014 Jun; 20(7):830-6. PubMed ID: 24277325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States.
    Araujo L; Kyatham S; Bzdek KG; Higuchi K; Greene N
    Clinicoecon Outcomes Res; 2023; 15():361-373. PubMed ID: 37234086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
    Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O
    BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis.
    Hersh CM; Brook RA; Beren IA; Rohrbacker NJ; Lebson L; Henke C; Phillips AL
    J Med Econ; 2021; 24(1):479-486. PubMed ID: 33739915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice.
    Hersh CM; Harris H; Conway D; Hua LH
    Neurol Clin Pract; 2020 Dec; 10(6):e53-e65. PubMed ID: 33510948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study.
    Tourbah A; Papeix C; Tourniaire P; Rerat K; Meite M; Durand B; Lamy F; Chouette I; Mekies C;
    Mult Scler Relat Disord; 2020 Nov; 46():102433. PubMed ID: 32862037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
    Duquette P; Yeung M; Mouallif S; Nakhaipour HR; Haddad P; Schecter R
    PLoS One; 2019; 14(1):e0210417. PubMed ID: 30640935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
    Derfuss T; Bergvall NK; Sfikas N; Tomic DL
    Curr Med Res Opin; 2015; 31(9):1687-91. PubMed ID: 26121423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
    Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
    Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.